Target type: biologicalprocess
The process in which a relatively unspecialized cell acquires the specialized features of a mononuclear cell. [CL:0000842, GO_REF:0000086, GOC:TermGenie, PMID:24759906]
Mononuclear cell differentiation is a complex and multifaceted process that involves the development of specialized immune cells from a common progenitor cell. It is a crucial step in the development of a functional immune system, enabling the body to mount effective responses against pathogens and other threats.
The process begins with a pluripotent hematopoietic stem cell (HSC) in the bone marrow. HSCs have the remarkable ability to differentiate into all types of blood cells, including mononuclear cells.
Under the influence of specific growth factors and cytokines, HSCs commit to the myeloid lineage, giving rise to common myeloid progenitors (CMPs). CMPs then further differentiate into various myeloid lineages, including the monocyte lineage.
Monocyte differentiation involves a series of regulated steps, including changes in gene expression, cell morphology, and functional capabilities. Monocytes are characterized by their large size, a single nucleus, and the presence of numerous cytoplasmic granules. They circulate in the bloodstream and play a critical role in innate immunity.
Upon reaching the tissues, monocytes can further differentiate into different subtypes of macrophages or dendritic cells, depending on the signals they receive from their environment.
Macrophages are phagocytic cells that engulf and destroy pathogens, cellular debris, and foreign particles. They also contribute to tissue repair and wound healing.
Dendritic cells act as antigen-presenting cells, capturing and presenting antigens to T lymphocytes, thereby initiating adaptive immune responses.
The differentiation of mononuclear cells is a highly regulated process, influenced by a variety of factors, including:
* **Growth factors and cytokines:** These signaling molecules stimulate cell proliferation and differentiation.
* **Transcription factors:** These proteins regulate gene expression, determining the specific fate of the differentiating cells.
* **Microenvironment:** The surrounding tissues and cells provide cues that guide cell differentiation.
Mononuclear cell differentiation is an ongoing process throughout life, ensuring the continuous replenishment of these essential immune cells. Dysregulation of mononuclear cell differentiation can lead to various diseases, including immunodeficiency and cancer.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cathepsin K | A cathepsin K that is encoded in the genome of human. [PRO:WCB, UniProtKB:P43235] | Homo sapiens (human) |
Proto-oncogene c-Fos | A protein c-Fos that is encoded in the genome of human. [PRO:DNx, UniProtKB:P01100] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
tryptamine | aminoalkylindole; aralkylamino compound; indole alkaloid; tryptamines | human metabolite; mouse metabolite; plant metabolite | |
masoprocol | nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata) | catechols; lignan; tetrol | antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite |
leupeptin | aldehyde; tripeptide | bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor | |
calpeptin | amino acid amide | ||
Pyrrolidine-1-carbonitrile | pyrrolidines | ||
dihydroguaiaretic acid | dihydroguaiaretic acid: lignan extracted form Larrea divaricata; inhibitory to beef heart mitochondrial succinoxidase & NADH-oxidase; RN given refers to cpd without isomeric designation | ||
nsc13345 | NSC13345: structure in first source | amidobenzoic acid | |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. | amino aldehyde; carbamate ester; tripeptide | proteasome inhibitor |
telaprevir | cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines | antiviral drug; hepatitis C protease inhibitor; peptidomimetic | |
relacatib | relacatib: a cathepsin K inhibitor; structure in first source | ||
a-705253 | A-705253: structure in first source | ||
l 006235 | |||
l-873724 | L-873724: a selective inhibitor of cathepsin K; structure in first source | ||
odanacatib | odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source | ||
balicatib | balicatib: cathepsin K inhibitor | ||
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. | tripeptide; ureas | antiviral drug; hepatitis C protease inhibitor; peptidomimetic |
PF-00835231 | PF-00835231 : A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity. | aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide | anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
mk-7009 | vaniprevir : An azamacrocyclic compound that is a hepatitis C virus (HCV) NS3/4A protease inhibitor which is approved for the treatment of hepatitis C virus infections in Japan. vaniprevir: inhibits hepatitis C virus NS3/4a protease | azamacrocycle; carbamate ester; cyclopropanes; N-sulfonylcarboxamide; pyrrolidinecarboxamide | antiviral drug; hepatitis C protease inhibitor |
vel-0230 | VEL-0230: a cathepsin K antagonist | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide | N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM). | aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide | anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |